Aptamers are small molecular ligands composed of short oligonucleotides that bind targets with high affinity. In contrast to antibodies, as synthetic oligonucleotides, aptamers have lower production costs and elicit no antigenic reactions. Therefore, aptamers are potential agents for disease diagnosis and treatment. In this study, we validate a fluorescently labeled RNA aptamer, which has been reported to bind specifically to mouse CD30 proteins in solution, for human CD30 protein recognition on intact cells. The aptamer probe was tested with cultured anaplastic large cell lymphoma and Hodgkin's lymphoma cells that express high levels of CD30. Flow cytometry and fluorescence microscopy showed specific and sensitive binding of the aptamer probe to CD30-expressing lymphoma cells at low concentrations (0.3 nM). Studies performed on multiple cell lines and nuclear cells from healthy donors confirmed that the CD30 aptamer and anti-CD30 antibody, the standard clinical probe, recognized the same set of cells. The potential application of multicolor flow cytometry analysis using the CD30 aptamer probe and antibodies was also shown. In conclusion, the developed CD30 aptamer probe could act as a replacement and/or a supplement for antibodies in the diagnosis of the CD30-expressing lymphomas.
In the past two decades, a new class of small molecule ligands composed of short oligonucleotides (usually 20-50 bases), known as 'aptamers', has been widely investigated. [1] [2] [3] [4] [5] [6] [7] Use of the systematic evolution of ligands by EXponential amplification technique has led to a variety of RNA or singlestranded DNA aptamers that have high binding affinity to their target molecules at pico-to nanomolar levels. 7, 8 Aptamers can virtually bind to all types of targets, including ions, toxins, drugs, low-molecular-weight ligands, peptides, proteins, and cells. A recent study that used the extracellular domain of the receptor activator of nuclear factor-kB (RANK) as a target identified an RNA aptamer that specifically binds to the tumor necrosis factor (TNF) receptor family proteins. 9 Interestingly, among its binding targets, this aptamer binds to mouse CD30 proteins with the highest affinity, more than 1000 times higher than other tested proteins among the TNF receptor family members in solution.
CD30 antigen is a transmembrane receptor that is normally expressed by activated T cells. 10 Abnormal expression of CD30 has been identified in tumor cells of anaplastic large cell lymphoma (ALCL) and Hodgkin's lymphoma. 11, 12 Detection of CD30 expression on tumor cells is a requirement for diagnosis of these lymphomas and for differentiating them from other types of tumors. 13 To date, the anti-CD30 antibody is the only probe that has been validated to detect cellular CD30 expression in clinical settings. 14 It is known that the binding of cell surface CD30 to its ligands could trigger complicated cellular responses and might be involved in the pathogenesis of the CD30-expressing neoplasms. [15] [16] [17] Thus, cellular CD30 receptor targeting represents a new therapeutic strategy for both diagnosing and treating ALCL. [18] [19] [20] [21] [22] In contrast to protein antibodies, aptamers are small, synthetic oligonucleotides, and therefore they are not antigenic in vivo and show better tissue/cell penetration. 7, 23 To validate the potential usage of aptamers in lymphoma diagnosis, we tested the previously identified RNA aptamer as a specific probe to detect the human CD30-expressing lymphoma cells. Furthermore, the usage of multicolor immunophenotyping was shown by combining the fluorescently labeled aptamer probe and antibodies.
MATERIALS AND METHODS
Cell Culture, Cell Preparation, and Reagents In this study, the human systemic ALCL cell lines Karpas 299 and SUDHL-1 were used in collaboration with Dr Mark Raffeld at the National Cancer Institute/National Institutes of Health. The human acute T-cell leukemia cell line Jurkat, human myeloid leukemia cell line K562, and human myeloma cell line RPMI8226 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human Hodgkin's lymphoma cell lines, L540, HDLM2, L428, and KMH2 were used in collaboration with Dr Barbara Savoldo at the Baylor College of Medicine (Houston, TX, USA). Cells were routinely cultured in RPMI-1640 medium (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), 100 units/ml penicillin, and 100 mg/ml streptomycin (Atlanta Biologicals, Lawrenceville, GA, USA) at 371C in a 5% CO 2 atmosphere.
For preclinical evaluation, nuclear cells were prepared from bone marrow aspirates from healthy donors under an Institutional Review Board approved protocol (n ¼ 10). In brief, 1 ml anticoagulant-treated bone marrow specimens were centrifuged at 500 g for 10 min, and nuclear cells within the Buffy coat between the serum and cell pellets were collected. Contaminated red blood cells (RBCs) were lysed by 6 ml of RBC lysis buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) at room temperature for 10 min. Unlysed nuclear cells were then washed with 2 ml phosphatebuffered saline (PBS, pH 7.4) and resuspended in cold PBS. In addition, to prepare fresh lymphoma cells, the patients' lymph nodes involved by follicular lymphoma (n ¼ 5) were digested by vigorous cutting and repeated pipetting to generate a cell suspension in cold PBS. The cells were then filtered through a 100 mm cup filcon (BD Medimachine, San Jose, CA, USA) to obtain a single-cell suspension.
Preparation of RNA Aptamer Probe Specific for CD30
According to the reported aptamer sequences, 9 a 39-mer nucleotide RNA aptamer was synthesized with one minor modification: 5 0 -gauUCGUAUGGGUGGGAUCGGGAAGGG CUACGAACAccg-3 0 (Bio-Synthesis, Inc., Lewisville, TX, USA). The synthesized aptamer probe contains the most essential functional motif and has the highest affinity to mouse CD30 molecules in solution. 9 To enhance its resistance to nucleases, the first three nucleotides on each end of the aptamer were synthesized with 2 0 -O-methyl modification (indicated by lower case letters). The predicted 3D structure of the aptamer is shown in Figure 1a . For tracking purposes, the synthesized aptamers were labeled with the fluorochrome cyanine dye, Cy5, at the 5 0 end. The aptamers were purified by high performance liquid chromatography and stored at À201C until use. To rule out nonspecific cell binding, a control 39-mer RNA probe was synthesized with a random sequence and also labeled with the Cy5 reporter: 5 0 -gau-random rN (n ¼ 33)-ccg-3 0 (Figure 1a ). Figure 2 . After confirmation, the optimized binding buffer (PBS, pH 7.4) containing 1 mM MgCl 2 and 0.1% BSA was used throughout the remaining experiments. To determine the optimal concentration of the CD30 aptamer probe, a dosing experiment was performed using different concentrations of aptamer probes (0-3 nM) as described in Figure 2 . A standard concentration for cell binding assays of the 0.3 nM CD30 aptamer was selected for all additional experiments.
To validate the binding specificity of the CD30 aptamer, various cultured lymphoma and leukemia cell lines were used as listed in Table 1 . Cells were incubated with the Cy5-labeled CD30 aptamer, as described above, or the fluorescein isothiocyanate (FITC)-labeled anti-CD30 antibody (BD Biosciences), a standard probe for examining CD30-expressing cells in clinical laboratories. For cell staining, the 0.3 nM CD30 aptamer or 1:20 diluted anti-CD30 antibody was added to 5 Â 10 5 cells in 100 ml binding buffer and incubated at room temperature for 20 min. After washing with binding buffer without BSA, probe or antibody binding was detected by flow cytometry analysis. For further validation, nuclear cells from healthy donor bone marrow (n ¼ 10), which included granulocytes, monocytes, lymphocytes, and nuclear RBCs, and fresh lymphoma cells from patients' lymph nodes involved by follicular lymphoma (n ¼ 5) were stained with the CD30 aptamer or anti-CD30 antibody.
To examine whether the CD30 aptamer and CD30 antibody compete for the same binding site on the CD30 protein, cultured Karpas 299 cells (5 Â 10 5 ) were co-stained with the Cy5-labeled CD30 aptamer (0.3 nM) and FITC-labeled CD30 antibody (1:20 dilution) for 20 min. Cell staining by each probe was evaluated by flow cytometry analysis.
To determine whether the CD30 aptamer probes could be combined with other antibodies to produce multicolor cell staining, phycoerythrin (PE)-labeled anti-CD25 antibody, FITC-labeled anti-CD30 antibody, and AmCyan-labeled anti- To detect ALCL cells in a heterogeneous cell specimen, fresh nucleated cells (5 Â 10 5 ) from the bone marrows of healthy donors were prepared by lysing the RBCs using RBC lysis buffer as described above. A small amount of cultured Karpas 299 cells (B0.5-13% of total cellularity) were added into the marrow cell specimens and the mixed cells were incubated simultaneously with the Cy5-labeled CD30 aptamer, AmCyan-labeled anti-CD45 antibody, and FITC-labeled anti-CD30 antibody for 20 min as described above. Stained cells were washed once and flow cytometry analysis was performed using an LSRII flow cytometer with three-color channels. The individual cellular populations in the cell mixture were separated and gated according to their distribution on the side scatter (SSC) vs CD45 panels following standard protocol for clinical flow cytometry (Figure 7a ). Cellular CD30 expression in each gated cell population was examined using both the CD30 aptamer probe and anti-CD30 antibody, and the numbers of detected CD30-positive Karpas 299 cells were compared.
Cell Staining Analysis of CD30 Aptamer Probes by Fluorescence Microscopy
Specific CD30 binding of aptamer was further examined using fluorescence microscopy. In this experiment, CD30-negative Jurkat cells (1 Â 10 6 ) were pre-labeled with 25 nM of carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen, Eugene, OR, USA) in 1 ml of PBS in the dark at 371C for 15 min. 24 The cells were then washed with PBS once and recultured in 4 ml fresh RPMI 1640 medium containing 10% FBS for 30 min before use. A cell mixture was prepared by mixing the CFSE-labeled Jurkat cells (5 Â 10 5 ) with an equal number of fresh Karpas 299 cells in binding buffer. Cy5-labeled CD30 aptamer probe (0.3 nM) was added to the cell mixture and incubated at room temperature for 20 min. After washing, slides of cell smears were prepared and examined under a fluorescent microscope.
RESULTS

RNA Aptamer Specifically Binds to Cultured Human CD30-Expressing Lymphoma Cells
To test whether the reported RNA aptamer recognizes proteins of the mouse TNF receptor family and is able to bind to Flow cytometry analysis using an aptamer probe P Zhang et al human CD30 on intact cells, a 39-mer RNA aptamer was synthesized according to the published sequence 9 and labeled with fluorochrome Cy5 (Figure 1a) . The first three nucleotides on each end of the aptamer were replaced with 2 0 -O-methyl nucleotides for better nuclease resistance (indicated by arrows). To assess cell binding, Karpas 299 and SUDHL-1 cells, which are human ALCL cell lines that characteristically express high levels of CD30 on their surfaces, were tested. Jurkat cell, a human T-cell leukemia cell line that does not express CD30, was used as a negative control. Cells were incubated with the CD30 aptamer probes (0.3 nM) in binding buffer for 20 min at room temperature, and resultant cell binding of the CD30 aptamer probe was quantitated by flow cytometry analysis. As shown in Figures 1b-d (Figures 2a and b) , but had little effect on nonspecific aptamer binding to Jurkat cells. The addition of BSA resulted in a significant increase in CD30 aptamer binding to Karpas 299 cells with a maximal effect at 0.1% concentration, and also reduced nonspecific binding to Jurkat cells (Figure  2c) , thereby increasing the overall specificity of CD30 aptamer-cell binding. Similar CD30 aptamer-cell binding patterns were observed with SUDHL-1 cells (data not shown). Thus, PBS buffer containing 1 mM MgCl 2 and 0.1% BSA was used as the standard binding buffer in all further experiments. Thereafter, a dosing study was performed to determine optimal concentration of CD30 aptamer for cell binding. As shown in Figures 2d and 2e , CD30 aptamer had a high affinity to Karpas 299 and SUDHL-1 cells and reached saturation after 1 nM. In contrast, the CD30 aptamer showed minimal nonspecific binding to Jurkat cells (Figure 2f) .
To rule out nonspecific binding of RNA aptamer to cultured cells, a 39-mer randomized control RNA aptamer probe was synthesized (Figure 1a ) and tested. As expected, flow cytometry analysis showed that this randomized control probe had little Table 1 ).
For further validation, nuclear cells, including granulocytes, monocytes, lymphocytes, and nuclear RBCs, from marrow aspirates of healthy donors (n ¼ 10) were prepared. Cells from fresh lymph node tissue sections of follicular lymphoma patients (n ¼ 5) were also prepared as described Flow cytometry analysis using an aptamer probe P Zhang et al in 'Materials and Methods.' The fresh cells were probed by the AmCyan-labeled anti-CD45 (common leukocyte antigen) antibody and Cy5-labeled CD30 aptamer. In the control group, the FITC-labeled anti-CD30 antibody was used instead of the CD30 aptamer. Stained cells were analyzed by flow cytometry, and populations of granulocytes, monocytes, and lymphocytes were gated according to their distribution on the side scatter vs CD45 panels. Subsequently, cell binding of the CD30 aptamer to the gated individual cell populations was evaluated and compared with that of the anti-CD30 antibody. The CD30 targeting aptamer and the anti-CD30 antibody showed identical cell staining patterns (Table 1) . Flow cytometry analysis using an aptamer probe P Zhang et al not express CD30 showed no label with either probes (Figures 5e-h ).
Immunophenotyping of Cells by a Combination of the CD30 Aptamer and Antibodies
Advanced flow cytometry enables simultaneous detection of multiple biomarkers on individual cells. Specific type of cells could be identified and isolated by simultaneously using multiple specific probes that are labeled with different fluorochromes. Thus, it is interesting to determine whether the CD30 aptamer probe could be used in combination with other antibodies for multicolor cell staining. To answer this question, cells were incubated with a staining solution consisting of the Cy5-labeled aptamer probe specific for CD30 (a cell marker for ALCL and Hodgkin's lymphoma), and with a PE-labeled antibody specific for CD25 (a lymphocyte activation marker that is expressed by activated T and B cells as well as ALCL cells), AmCyan-labeled antibody specific for CD45, or FITC-labeled antibody specific for CD30. As shown in Figures 6a-f , Karpas 299 cells and SUDHL-1 cells were simultaneously stained by the CD30 aptamer probe and antibodies against CD25, CD30, and CD45. In the control group, Jurkat cells showed no staining by antibodies to CD25 or CD30 (both aptamer and antibody probes), but positive staining by the CD45 antibody as expected (Figures 6g-i) . 
DISCUSSION
Currently, antibodies are generally the only available clinical probes for lymphoma diagnosis. 25 The study has shown that an RNA aptamer possesses identical specificity and sensitivity to those of anti-CD30 antibodies. Our results suggested that the CD30-specific aptamer could replace the anti-CD30 antibody in flow cytometry analysis. In addition, multicolor staining of cultured cells indicates that the CD30 aptamer probe can be used in combination with antibodies in multiparameter flow cytometry analysis for lymphoma diagnosis. It will be interesting to explore the use of CD30 aptamer probes for immunohistochemical staining of fixed tissue sections for the diagnoses of CD30-associated diseases, including ALCL and Hodgkin's Lymphomas. Before clinical application of the CD30 aptamer probe, a large-scale validation study with samples from both normal donors and lymphoma patients should be performed.
In comparison with antibodies, oligonucleotide aptamers, such as those synthesized in this work, have unparalleled advantages for clinical use. As a small molecule, aptamers are not antigenic and can be synthesized at a significantly lower cost than antibodies. 26 In addition, aptamers can be easily modified and labeled with fluorescent, optical, or radioisotope reporters as needed for tracking purposes. 4, 6, 7, 23 These features increase the potential of aptamers for the in vivo application as diagnostic/therapeutic agents. Our findings indicate that the aptamer probe can be used in combination with antibodies for multicolor cell immunophenotyping analysis, and it may be a suitable replacement for the anti-CD30 antibody in disease diagnosis (Figure 7) . In addition, studies using antibodies have revealed that the binding of the CD30 receptors results in the activation of the cellular signaling pathways that lead to the growth arrest and Flow cytometry analysis using an aptamer probe P Zhang et al death of ALCL cells in vitro. 20, [27] [28] [29] These findings suggest that the CD30 receptors may also be a therapeutic target for ALCL treatment. To understand whether the binding of aptamers to the CD30 receptors has any intracellular effect, we have exposed cultured ALCL cells (Karpas 299 and SUDHL-1) to the CD30 aptamer; however, the synthesized aptamer had no effect on cell growth as assessed by the MTT assay (unpublished result). It is notable that in contrast to antibodies that contain two binding sites to the CD30 receptors, the CD30 aptamer probes have only a single binding site that is not able to crosslink and activate the CD30 receptors on the cell surface.
Aptamers, especially the RNA-based aptamers, are susceptible to degradation by environmental nucleases, largely limiting their clinical value to date. However, chemical modification with 2 0 -O-methyl or 2-fluoro nucleic acids, phosphorothioate linkages, or a combination of these has been reported to significantly improve the nuclease resistance of the RNA-based aptamers. [30] [31] [32] [33] [34] Considering the rapidly advancing synthesis technologies, we believe that aptamers could become powerful diagnostic and therapeutic agents in the near future. Flow cytometry analysis using an aptamer probe P Zhang et al
